Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Biogen stock

BIIB
US09062X1037
789617

Price

161.61
Today +/-
+8.40
Today %
+5.53 %

Biogen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biogen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biogen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biogen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biogen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biogen Stock Price History

DateBiogen Price
1/2/2025161.61 undefined
12/31/2024152.92 undefined
12/30/2024150.19 undefined
12/27/2024151.31 undefined
12/26/2024149.90 undefined
12/24/2024149.02 undefined
12/23/2024149.38 undefined
12/20/2024146.47 undefined
12/19/2024147.39 undefined
12/18/2024146.79 undefined
12/17/2024150.64 undefined
12/16/2024150.49 undefined
12/13/2024150.03 undefined
12/12/2024155.33 undefined
12/11/2024157.46 undefined
12/10/2024156.32 undefined
12/9/2024156.46 undefined
12/6/2024157.78 undefined
12/5/2024159.26 undefined
12/4/2024160.92 undefined

Biogen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biogen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biogen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biogen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biogen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biogen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biogen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biogen’s growth potential.

Biogen Revenue, EBIT and net profit per share

DateBiogen RevenueBiogen EBITBiogen Net Income
2029e10.66 B undefined3.47 B undefined2.98 B undefined
2028e10.43 B undefined3.55 B undefined3.01 B undefined
2027e10.16 B undefined3.38 B undefined2.82 B undefined
2026e9.94 B undefined3.24 B undefined2.64 B undefined
2025e9.73 B undefined3.09 B undefined2.49 B undefined
2024e9.83 B undefined3.09 B undefined2.44 B undefined
20239.84 B undefined2.17 B undefined1.16 B undefined
202210.17 B undefined3.22 B undefined3.05 B undefined
202110.98 B undefined3.5 B undefined1.56 B undefined
202013.45 B undefined4.98 B undefined4 B undefined
201914.38 B undefined7.56 B undefined5.89 B undefined
201813.45 B undefined6.57 B undefined4.43 B undefined
201712.27 B undefined5.58 B undefined2.54 B undefined
201611.45 B undefined5.66 B undefined3.7 B undefined
201510.76 B undefined4.98 B undefined3.55 B undefined
20149.7 B undefined3.96 B undefined2.94 B undefined
20136.93 B undefined2.58 B undefined1.86 B undefined
20125.52 B undefined2.13 B undefined1.38 B undefined
20115.05 B undefined2.06 B undefined1.23 B undefined
20104.72 B undefined1.83 B undefined1 B undefined
20094.38 B undefined1.51 B undefined968 M undefined
20084.1 B undefined1.37 B undefined782 M undefined
20073.17 B undefined877 M undefined637 M undefined
20062.68 B undefined738 M undefined217 M undefined
20052.42 B undefined354 M undefined160 M undefined
20042.21 B undefined43 M undefined25 M undefined

Biogen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.010.010.010.010.010.010.020.030.050.090.120.160.270.40.682.212.422.683.174.14.384.725.055.526.939.710.7611.4512.2713.4514.3813.4510.9810.179.849.839.739.9410.1610.4310.66
-16.67-14.29-16.67160.00-46.15242.8625.0050.0093.3335.6331.3676.1347.9968.07225.779.5410.7318.2329.196.817.757.069.2525.6739.9710.936.367.219.616.88-6.49-18.32-7.37-3.32-0.04-1.082.172.282.632.20
100.00100.00100.00100.00100.00100.00100.00100.0057.7877.0188.1498.71100.0099.7558.0374.9184.5689.7989.4190.1991.2791.5290.7590.1287.6287.9388.4787.0886.7286.5086.4086.5780.7977.6175.5175.5476.3674.7473.0771.2069.67
0.010.010.010.010.010.010.020.030.030.070.10.150.270.40.391.662.052.412.843.744.324.584.976.078.539.529.9710.6411.6412.4211.648.877.97.43000000
-0-0-0.01-0.01-0.01-0.02-0.02-0.01-0.020.020.040.050.10.15-0.880.030.160.220.640.780.9711.231.381.862.943.553.72.544.435.8941.563.051.162.442.492.642.823.012.98
-33.3350.00116.67-30.77100.00-5.56-64.71166.67-231.25104.7611.63112.5045.10-691.22-102.86540.0035.63193.5522.7623.793.6223.0311.8334.9357.6320.854.40-31.4374.5232.90-32.06-61.1195.82-61.90109.732.056.366.626.71-1.06
2930395556668899112140151159181180178343346345320295289255245240238237231219213205187161150146145.6000000
-----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Biogen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biogen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                 
0.040.040.030.020.020.080.070.070.250.580.620.790.841.060.850.91.181.371.261.211.691.711.221.853.434.93.693.544.482.613.84.891.05
00000000.020.030.040.070.110.320.420.420.490.560.650.750.830.810.961.081.581.541.742.322.492.472.331.962.142.1
101010000000003250251316120000000000000
00000000.010000.030.50.250.180.170.230.260.290.290.330.450.660.80.8910.90.930.81.071.351.342.53
000000000.010.010.020.050.190.210.150.10.370.160.160.20.150.140.230.310.841.090.960.690.630.880.741.421.18
0.040.040.030.020.030.090.080.10.280.630.710.981.841.931.631.712.372.462.482.542.983.243.194.546.78.737.887.648.386.897.869.796.86
000.020.020.020.020.020.020.020.050.110.271.251.531.171.281.51.61.641.641.571.741.751.772.192.53.183.63.673.853.793.73.73
0.020.0100000000.170.240.661.51.271.471.661.131.131.420.991.752.311.222.223.874.164.063.042.653.672.832.240.75
032210000000000000000000000000000
000000000000.013.643.292.982.752.492.161.871.771.611.634.484.034.093.813.883.123.533.082.221.858.36
0000000000001.151.151.131.161.141.141.141.151.151.21.231.762.663.674.635.715.765.765.765.756.22
000000000.010.010.080.150.120000000000000.010.032.183.241.371.421.230.93
0.020.010.020.020.020.020.030.020.030.230.431.087.677.246.756.846.266.026.075.556.076.898.689.7812.8114.1515.7817.6518.8517.7316.0214.7619.99
0.060.050.050.050.050.110.110.130.310.861.142.069.59.178.388.558.638.488.558.099.0510.1311.8614.3219.5122.8823.6625.2927.2324.6223.8824.5526.84
                                                                 
767778881080000000000000000000000000000.1
000000.180.180.180.20.680.840.987.88.198.218.315.816.075.783.94.193.864.024.2000.10000.070.070.3
-0.02-0.04-0.04-0.06-0.08-0.08-0.1-0.08-0.040.010.120.26-0.61-0.8-1.02-0.86-0.350.271.071.873.114.496.359.2812.2115.0715.8116.2616.4613.9813.9116.4717.63
00000000-1114-1-43-572279-1139-34-27-60-33-59-223-309-317-236-139-300-105-149-153.7
00000000000000000011120460-1-11-2-441-2-160
0.060.040.040.030.030.090.080.110.160.70.961.257.197.347.137.475.536.336.95.757.278.2910.3513.4211.9814.7515.5916.0216.3213.6813.8716.3817.78
1473132212446312110010091107119163186204220229267280396371531455589492403.3
000000.010.010.010.010.020.030.050.240.250.30.340.370.540.460.480.260.490.771.051.11.511.241.551.681.721.471.591.66
0000000.01000000.10.140.20.150.220.250.120.270.460.520.770.941.21.631.731.381.161.571.241.191.22
000000000000000000000000000000000
00000000000000.75001.510.030.020.1400.45000.010.01001.50100.15
00.010.010.010.010.010.020.010.020.020.030.060.41.260.60.582.190.920.721.050.911.661.762.222.583.423.373.34.873.744.33.273.43
0000.010.010.01000.120.130.140.870.890.10.040.10.051.091.081.071.060.690.590.586.526.515.945.944.467.436.276.286.79
0000000000.01001.110.920.760.640.520.360.240.20.250.220.230.050.130.090.121.642.811.030.70.340.64
000000000.0100.020.030.050.060.070.080.330.280.250.330.40.60.660.650.910.721.631.391.761.731.651.281.18
0000.010.010.010.0100.130.140.150.892.051.080.880.820.911.721.581.591.711.511.481.287.557.337.698.969.0310.198.627.898.61
00.010.020.020.020.020.030.020.150.160.190.952.452.341.481.43.12.642.292.642.623.173.243.510.1310.7511.0612.2613.913.9312.9211.1712.05
0.060.050.050.050.050.110.110.120.310.861.142.29.649.688.68.878.638.989.198.399.8911.4513.5916.9222.1125.526.6428.2830.2227.6126.7927.5429.82
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biogen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biogen's financial health and stability.

Assets

Biogen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biogen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biogen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biogen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0-0.01-0.01-0.01-0.02-0.02-0.01-0.020.020.040.060.10.15-0.880.030.160.220.580.790.980.91.271.381.862.943.593.72.674.475.894.061.732.961.16
000000000000.010.010.060.440.40.380.380.460.430.360.360.370.530.690.60.681.081.020.680.460.490.520.49
00000000001160-39-27-135-115-106-81-139-137-81153-116-245-308-145-1759110867149-426-168-305
0013-40-38-20-3-9-19-61-130-17699-103-79174-3513-18410387-484-450125235400199-187-145-890-648
000000.010000.01-00.010.141.140.590.380.580.340.420.320.620.250.270.250.260.480.410.60.350.43-0.052.24-0.781.11
00000111000000038035406868666553410281281243244272280262252
00000000000000.0400.090.40.250.370.75-0.39-0.33-0.530.641.1601.641.071.011.060.910.250.930.74
-0-0.01-0.01-0-0.02-0-0-00.010.050.060.150.20.170.730.890.841.021.561.071.621.731.882.352.943.924.594.556.197.084.233.641.381.55
00-1-17-1-1-6-5-1-4-31-67-165-301-369-318-198-284-276-165-173-252-261-3,509-287-658-727-1,962-886-669-551-294-243-311
-0-0.04000.010-0.050.01-0.01-0.14-0.2-0.16-0.86-0.26-0.380.42-0.6-0.29-0.37-0.40.35-1.65-0.95-1.6-1.54-4.55-2.48-2.96-2.050.47-0.61-0.561.58-4.1
-0-0.0400.020.010-0.050.02-0.01-0.14-0.16-0.09-0.690.04-0.010.74-0.4-0-0.09-0.230.52-1.4-0.691.9-1.26-3.9-1.76-1-1.161.14-0.06-0.271.82-3.79
0000000000000000000000000000000000
00000.01-0-0-0-00.11-000.70.030.01-0.75-0.011.49-0.5300.11-0.01-0-0.45-05.93-0-0.56-001.47-0.17-10.19
3541010865341447428-11124-460-203-173-2,502-560-703-1,894-183-917-333-831-5,000-1,000-1,365-4,352-5,868-6,679-1,800-7500
3541516664201254722758451-451-948-148-733-1,234-724-1,784-319-877-716-755783-1,052-2,380-4,472-5,860-5,272-2,086-1,747149
000000000000000031279-148-220-125426978-145-49-453-1167-61-1164-38
0000000000000000000000000000000000
-00.01-0.01000.010.010.01-0.010.030.340.03-0.08-0.04-0.110.360.09-0-0.04-0.040.18-0.250.060.030.60.11.02-0.75-0.351.69-1.580.931.16-2.37
-3.6-6.5-11.7-22-20.7-3.9-10.1-8.73.448.230.686.930.8-131.2358.2571.1643734.71,286.4909.31,451.61,475.51,618.7-1,163.92,654.33,2613,859.52,588.25,301.66,409.13,6783,3451,141.11,235.8
0000000000000000000000000000000000

Biogen stock margins

The Biogen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biogen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biogen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biogen's sales revenue. A higher gross margin percentage indicates that the Biogen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biogen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biogen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biogen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biogen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biogen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biogen Margin History

Biogen Gross marginBiogen Profit marginBiogen EBIT marginBiogen Profit margin
2029e75.51 %32.54 %27.92 %
2028e75.51 %34 %28.84 %
2027e75.51 %33.24 %27.73 %
2026e75.51 %32.58 %26.61 %
2025e75.51 %31.79 %25.56 %
2024e75.51 %31.45 %24.77 %
202375.51 %22.11 %11.81 %
202277.61 %31.69 %29.95 %
202180.79 %31.82 %14.17 %
202086.57 %37 %29.76 %
201986.4 %52.57 %40.96 %
201886.5 %48.8 %32.94 %
201786.72 %45.44 %20.69 %
201687.08 %49.44 %32.34 %
201588.47 %46.3 %32.95 %
201487.93 %40.76 %30.25 %
201387.62 %37.16 %26.86 %
201290.12 %38.6 %25.02 %
201190.75 %40.84 %24.44 %
201091.52 %38.74 %21.27 %
200991.27 %34.54 %22.12 %
200890.19 %33.31 %19.08 %
200789.41 %27.65 %20.08 %
200689.79 %27.51 %8.09 %
200584.56 %14.61 %6.6 %
200474.91 %1.94 %1.13 %

Biogen Stock Sales Revenue, EBIT, Earnings per Share

The Biogen earnings per share therefore indicates how much revenue Biogen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biogen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biogen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biogen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biogen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biogen Revenue, EBIT and net profit per share

DateBiogen Sales per ShareBiogen EBIT per shareBiogen Earnings per Share
2029e73.15 undefined0 undefined20.42 undefined
2028e71.58 undefined0 undefined20.64 undefined
2027e69.74 undefined0 undefined19.34 undefined
2026e68.19 undefined0 undefined18.14 undefined
2025e66.74 undefined0 undefined17.06 undefined
2024e67.47 undefined0 undefined16.71 undefined
202367.55 undefined14.93 undefined7.97 undefined
202269.68 undefined22.08 undefined20.87 undefined
202173.21 undefined23.3 undefined10.37 undefined
202083.51 undefined30.9 undefined24.85 undefined
201976.89 undefined40.42 undefined31.49 undefined
201865.62 undefined32.02 undefined21.61 undefined
201757.62 undefined26.18 undefined11.92 undefined
201652.28 undefined25.84 undefined16.91 undefined
201546.6 undefined21.58 undefined15.35 undefined
201440.94 undefined16.69 undefined12.38 undefined
201329.13 undefined10.82 undefined7.82 undefined
201222.98 undefined8.87 undefined5.75 undefined
201120.61 undefined8.42 undefined5.04 undefined
201018.49 undefined7.16 undefined3.93 undefined
200915.15 undefined5.23 undefined3.35 undefined
200813.89 undefined4.63 undefined2.65 undefined
20079.91 undefined2.74 undefined1.99 undefined
20067.78 undefined2.14 undefined0.63 undefined
20057 undefined1.02 undefined0.46 undefined
20046.45 undefined0.13 undefined0.07 undefined

Biogen business model

Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen is one of the most popular companies on Eulerpool.com.

Biogen SWOT Analysis

Strengths

Biogen Inc is a prominent biotechnology company with a strong presence in the industry. It has a solid track record of developing innovative drugs and therapies.

Biogen Inc offers a diversified range of products, including treatments for multiple sclerosis, spinal muscular atrophy, and hemophilia. This diversified portfolio reduces its dependency on a single product and contributes to its overall revenue stability.

The company invests significantly in research and development, allowing it to stay at the forefront of medical advancements and develop cutting-edge therapies.

Weaknesses

Biogen Inc heavily relies on a few key products, such as Tecfidera and Spinraza, for a significant portion of its revenue. This creates vulnerability if any of these products face challenges or competition.

As a biotechnology company, Biogen Inc faces regulatory risks associated with drug approvals and ongoing compliance. Changes in regulatory policies can impact the company's ability to bring new products to market or maintain existing product lines.

Opportunities

The global biopharmaceutical market is expanding rapidly, providing significant growth opportunities for Biogen Inc. The company can leverage its expertise and expand into new regions to capture a larger market share.

Biogen Inc can benefit from investing in innovative technologies, such as gene therapies and personalized medicine. These advancements have the potential to revolutionize the healthcare industry and offer new avenues for growth.

Threats

Biogen Inc operates in a highly competitive industry with several other major pharmaceutical and biotechnology companies. Intense competition can impact pricing, market share, and profitability.

Protecting intellectual property rights is crucial for Biogen Inc, as competitors may attempt to replicate or challenge its products. Any infringement or loss of intellectual property could negatively impact the company's revenue and market position.

Biogen Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Product, net-7.99 B USD8.85 B USD10.69 B USD11.38 B USD4.09 B USD
Product revenue, net7.25 B USD-----
Revenue from anti-CD20 therapeutic programs1.69 B USD1.7 B USD1.66 B USD---
Revenues from anti-CD20 therapeutic programs---1.98 B USD--
Other-485.1 M USD476.3 M USD774.6 M USD--
Contract manufacturing, royalty and other revenue899.3 M USD-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
SPINRAZA1.74 B USD---2.1 B USD870.2 M USD
Subtotal: Multiple Sclerosis4.66 B USD-----
TYSABRI1.88 B USD-----
Subtotal: Rare Disease1.8 B USD-----
Total Fumarate1.59 B USD-----
Biosimilars----738.3 M USD545.1 M USD
Other corporate--427.7 M USD719.1 M USD--
Total Interferon1.11 B USD-----
TECFIDERA1.01 B USD-----
AVONEX811 M USD-----
Subtotal: Biosimilars770 M USD-----
VUMERITY576.3 M USD---5.5 M USD-
BENEPALI438.8 M USD-----
IMRALDI222.1 M USD---184 M USD16.7 M USD
Contract manufacturing and other revenue-417.7 M USD----
PLEGRIDY294.7 M USD-----
FAMPYRA90.5 M USD-----
FLIXABI77.4 M USD-----
Completed technology for SKYCLARYS (U.S.)55.9 M USD-----
BYOOVIZ31.7 M USD-----
Other11.8 M USD-----
QALSODY5.9 M USD-----
ZINBRYTA-----1.4 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Revenues from anti-cd20 therapeutic programs----2.29 B USD200,000 USD
Royalty Attributed To OCREVUS-1.14 B USD----
Contract manufacturing revenue848.2 M USD-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
TECFIDERA----4.43 B USD1.02 B USD
Royalty revenue on sales of OCREVUS1.27 B USD-----
Royalty revenue-67.4 M USD----
Royalty--27.9 M USD33.9 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Other revenue----707.7 M USD206.7 M USD
Royalty and other revenue51.1 M USD-----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Subtotal: MS-5.43 B USD6.1 B USD7.83 B USD--
Fumarate-2 B USD2.36 B USD3.91 B USD--
TYSABRI-2.03 B USD2.06 B USD1.95 B USD--
SPINRAZA-1.79 B USD1.91 B USD2.05 B USD--
Interferon-1.31 B USD1.57 B USD1.88 B USD--
Subtotal: Biosimilars-751.1 M USD831.1 M USD795.8 M USD--
TECFIDERA-1.44 B USD----
BENEPALI-441 M USD498.3 M USD481.6 M USD--
AVONEX-973.5 M USD----
IMRALDI-224.5 M USD233.4 M USD216.3 M USD--
VUMERITY-553.4 M USD----
PLEGRIDY-331.9 M USD----
FAMPYRA-96.6 M USD105.2 M USD103.1 M USD--
FLIXABI-81.3 M USD99.4 M USD97.9 M USD--
FUMADERM-8.2 M USD11 M USD12.2 M USD--
ADUHELM-4.8 M USD3 M USD---
BYOOVIZ-4.3 M USD----
ZINBRYTA------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
TYSABRI----1.89 B USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
MS Product Revenues----8.53 B USD-
Interferon----2.1 B USD-
BENEPALI----486.2 M USD-
FAMPYRA----97.1 M USD-
FLIXABI----68.1 M USD-
FUMADERM----15.2 M USD-
ALPROLIX------
ELOCTATE------
Hemophilia Products------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
MS Product Revenues-----2.65 B USD
Interferon-----694.7 M USD
Other corporate revenues----584.5 M USD-
BENEPALI-----485.2 M USD
FAMPYRA-----92.7 M USD
FLIXABI-----43.2 M USD
FUMADERM-----22.3 M USD
ALPROLIX------
ELOCTATE------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Other corporate revenues-----459.4 M USD
Royalty----17 M USD38.7 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
Hemophilia Products------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biogen Revenue by Segment

Segmente202320222021202020192018
TYSABRI-----839 M USD

Biogen Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Biogen Revenue by Segment

DateForeignU.S
20181.4 M USD-8.6 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biogen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biogen historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biogen shares outstanding

The number of shares was Biogen in 2024 — This indicates how many shares 145.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biogen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biogen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biogen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biogen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biogen stock splits

In Biogen's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Biogen.

Biogen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20243.87 4.08  (5.5 %)2024 Q3
6/30/20244.11 5.28  (28.6 %)2024 Q2
3/31/20243.52 3.67  (4.32 %)2024 Q1
12/31/20233.25 3.3  (1.62 %)2023 Q4
9/30/20234.05 4.36  (7.59 %)2023 Q3
6/30/20233.84 4.02  (4.66 %)2023 Q2
3/31/20233.34 3.4  (1.66 %)2023 Q1
12/31/20223.55 4.05  (13.99 %)2022 Q4
9/30/20224.22 4.77  (13.06 %)2022 Q3
6/30/20224.14 5.25  (26.66 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Biogen stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

79

👫 Social

85

🏛️ Governance

57

Environment

Scope 1 - Direct Emissions
64,867
Scope 2 - Indirect emissions from purchased energy
31,765
Scope 3 - Indirect emissions within the value chain
434,635
Total CO₂ emissions
96,632
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees52.8
Percentage of women in management
Percentage of Asian employees17.6
Share of Asian management19.7
Percentage of Hispanic/Latino employees3.8
Hispano/Latino Management share3.6
Percentage of Black employees10.7
Black Management Share5.5
Percentage of white employees59.2
White Management Share63.4
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biogen shareholders

%
Name
Stocks
Change
Date
11.34895 % The Vanguard Group, Inc.16,537,68728,8346/30/2024
11.21212 % PRIMECAP Management Company16,338,294117,5786/30/2024
5.72210 % BlackRock Institutional Trust Company, N.A.8,338,243133,6666/30/2024
5.04152 % State Street Global Advisors (US)7,346,505250,4879/30/2024
3.89710 % T. Rowe Price Investment Management, Inc.5,678,859508,8896/30/2024
3.54549 % Wellington Management Company, LLP5,166,49146,3496/30/2024
2.44713 % Geode Capital Management, L.L.C.3,565,965156,2916/30/2024
1.97353 % JP Morgan Asset Management2,875,833-16,2196/30/2024
1.93905 % Invesco Capital Management (QQQ Trust)2,825,58114,7989/30/2024
1.42653 % Norges Bank Investment Management (NBIM)2,078,745615,1746/30/2024
1
2
3
4
5
...
10

Biogen Executives and Management Board

Mr. Christopher Viehbacher

(63)
Biogen President, Chief Executive Officer, Director (since 2022)
Compensation 30.49 M

Mr. Michael McDonnell

(59)
Biogen Chief Financial Officer, Executive Vice President
Compensation 7.21 M

Ms. Susan Alexander

(66)
Biogen Executive Vice President, Chief Legal Officer, Secretary
Compensation 6.79 M

Dr. Ginger Gregory

(55)
Biogen Chief Human Resource Officer, Executive Vice President
Compensation 5.08 M

Ms. Nicole Murphy

(50)
Biogen Executive Vice President - Pharmaceutical Operations and Technology
Compensation 4.93 M
1
2
3
4

Biogen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
2seventy Bio Stock
2seventy Bio
SupplierCustomer0,790,810,770,84
Kiniksa Pharmaceuticals A Stock
Kiniksa Pharmaceuticals A
SupplierCustomer0,790,860,800,840,770,28
Ginkgo Bioworks A Stock
Ginkgo Bioworks A
SupplierCustomer0,710,870,790,840,64
Sage Therapeutics, Inc. Stock
Sage Therapeutics, Inc.
SupplierCustomer0,620,790,750,860,850,25
Bristol-Myers Squibb Company Stock
Bristol-Myers Squibb Company
SupplierCustomer0,60-0,090,09-0,74-0,25-0,21
Roche Holding AG Stock
Roche Holding AG
SupplierCustomer0,590,600,750,690,11
Denali Thrptcs Stock
Denali Thrptcs
SupplierCustomer0,520,670,550,840,90
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,52-0,090,02-0,800,380,32
Bio-Thera Solutions A Stock
Bio-Thera Solutions A
SupplierCustomer0,480,770,410,700,550,16
Oxford BioDynamics Stock
Oxford BioDynamics
SupplierCustomer0,480,760,410,850,900,40
1
2
3

Most common questions regarding Biogen

What values and corporate philosophy does Biogen represent?

Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.

In which countries and regions is Biogen primarily present?

Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.

What significant milestones has the company Biogen achieved?

Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.

What is the history and background of the company Biogen?

Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.

Who are the main competitors of Biogen in the market?

The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.

In which industries is Biogen primarily active?

Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Biogen?

Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.

What is the P/E ratio of Biogen 2025?

The Biogen P/E ratio is 9.47.

What is the P/S ratio of Biogen 2025?

The Biogen P/S ratio is 2.42.

What is the Quality Investing of Biogen?

The Quality Investing for Biogen is 3/10.

What is the revenue of Biogen 2025?

The expected Biogen revenue is 9.73 B USD.

How high is the profit of Biogen 2025?

The expected Biogen profit is 2.49 B USD.

What is the business model of Biogen

Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.

What is the Biogen dividend?

Biogen pays a dividend of 0 USD distributed over payouts per year.

How often does Biogen pay dividends?

The dividend cannot currently be calculated for Biogen or the company does not pay out a dividend.

What is the Biogen ISIN?

The ISIN of Biogen is US09062X1037.

What is the Biogen WKN?

The WKN of Biogen is 789617.

What is the Biogen ticker?

The ticker of Biogen is BIIB.

How much dividend does Biogen pay?

Over the past 12 months, Biogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biogen is expected to pay a dividend of 0 USD.

What is the dividend yield of Biogen?

The current dividend yield of Biogen is .

When does Biogen pay dividends?

Biogen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biogen?

Biogen paid dividends every year for the past 0 years.

What is the dividend of Biogen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biogen located?

Biogen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biogen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biogen from 1/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Biogen pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Biogen in the year 2024?

In the year 2024, Biogen distributed 0 USD as dividends.

In which currency does Biogen pay out the dividend?

The dividends of Biogen are distributed in USD.

All fundamentals about Biogen

Our stock analysis for Biogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.